Table 1 Comparisons of clinical outcomes of ICBs between NSCLC and SCLC

NCT 00527735 [48]

II R 1: 1: 1

N = 204

1. Placebo+Pacl+Carbo

2. Concurrent Ipi+Pacl+Carbo

3. Phased Ipi+Pacl+Carbo

irBORR, 18%, 21%, 32%

mWHO-BORR, 14%, 21%, 32%

Median irPFS, 4.6 m, 5.5 m, 5.7 m

Median PFS, 4.2 m, 4.1 m, 5.1 m

Median OS, 8.3 m, 9.7 m, 12.2 m

G3-4

6%

20%

15%

NCT 00527735 [49]

II R 1: 1: 1

N = 130

1. Placebo+Pacl+Carbo

2. Concurrent Ipi+Pacl+Carbo

3. Phased Ipi+Pacl+Carbo

irBORR, 53%, 49%, 71%

mWHO-BORR, 49%, 33%, 57%

Median irPFS, 5.3 m, 5.7 m, 6.4 m

Median PFS, 5.2 m, 3.9 m, 5.2 m

Median OS, 9.9 m, 9.1 m,12.9 m

G3-4

9%

21%

17%

NCT01285609 [50]

III R 1: 1

N = 749

1. Phased Placebo+Pacl+Carbo

2. Phased Ipi+Pacl+Carbo

BORR, 47%, 44%

Median PFS, 5.6 m, 5.6 m

Median OS, 12.4 m, 13.4 m

G3-4

35%

51%

CA184-156 [51]

III R 1, 1

N = 954

1. Phased Placebo+Etop+Plat

2. Phased Ipi+Etop+Plat

BORR, 62%, 62%

Median PFS, 4.4 m, 4.6 m

Median OS, 10.9 m, 11.0 m

G3-5

11%

22%

IMpower131 [52]

III R 1: 1

N = 578

1. Atezo+Nab-Pacl+Carbo

2. Nab-Pacl+Carbo

ORR, 49%, 41%

Median PFS, 6.3 m, 5.6 m

Median OS, 14.0 m, 13.9 m

G3-5

67%

58%

IMpower133 [53]

III R 1: 1

N = 403

1. Atezo+Etop+Carbo

2. Placebo+Etop+Carbo

ORR, 60.2%, 64.4%

Median PFS, 5.2 m, 4.3 m

Median OS, 12.3 m, 10.3 m

G3-5

58.1%

57.6%

IMpower132 [54]

III R 1: 1

N = 403

1. Atezo+Pem+Plat

2. Placebo+Pem+Plat

ORR, 47%, 32%

Median PFS, 7.6 m, 5.2 m

Median OS,18.1 m, 13.6 m

G3-5

58.1%

57.6%

IMpower150 [55]

III R 1: 1

N = 692

1. Atezo+Bev+Pacl+Carbo

2. Bev+Pacl+Carbo

ORR, 63.5%, 48%

Median PFS, 8.3 m, 6.8 m

Median OS,19.2 m, 14.7 m

G3-5

58.5%

50%

CheckMate 017 [56]

Squamous

III R 1: 1

N = 272

1. Nivo

2. Docetaxel

ORR, 20%, 9%

Median PFS, 3.5 m, 2.8 m

Median OS, 9.2 m, 6.0 m

1-year OS, 42%, 24%

G3-4

7%

55%

CheckMate 032 [57]

I/II NR, N = 216

1. Nivo 3 mg/kg

2. Nivo 1 mg/kg + Ipi 3 mg/kg

3. Nivo 3 mg/kg + Ipi 1 mg/kg.

ORR, 10%, 23%, 19%

Median PFS, 1.4 m, 2.6 m, 1.4 m

Median OS, 4·4 m, 7.7 m, 6.0 m

1-year OS, 33%, 43%, 35%

G3-4

13%

30%

19%

CheckMate 057 [58]

Nonsquamous

III R 1: 1

N = 582

1. Nivo

2. Docetaxel

ORR, 19%, 12%

Median PFS,2.3 m, 4.2 m

Median OS, 12.2 m, 9.4 m

1-year OS, 51%, 39%

G3-4

10%

54%

CheckMate 331 [59]

III R 1: 1

N = 569

1. Nivo

2. Topotecan/Amrubicin

ORR, 13.7%, 16.5%

Median PFS, 1.5 m, 3.8 m

Median OS, 7.5 m, 8.4 m

1-year OS, 37%, 34%

G3-4

4.7%

74%

KEYNOTE-010 [60]

PD-L1 ≥ 1%

II/III R 1: 1: 1

N = 1034

1. Pembro 2 mg/kg,

2. Pembro 10 mg/kg

3. Docetaxel 75 mg/m²

ORR, 18%, 18%, 9%

Median PFS, 3.9 m, 4.0 m, 4.0 m

Median OS, 10·4 m, 12.7 m, 8.5 m

1-year OS, 43.2%, 52.3%, 34.6%

G3-5

13%

16%

35%

KEYNOTE-028

KEYNOTE-158 [61]

Ib/II N = 83

Pembro

ORR, 19.3%

Median PFS, 2.0 m

Median OS, 7.7 m

1-year OS, 20.7%

G3-5

8%

POPLAR [62]

II R 1: 1

N = 287

1. Atezo

2. Docetaxel

ORR, 15%, 15%

Median PFS, 2.7 m, 3.0 m

Median OS, 12.6 m, 9.7 m

G3-4

11%

39%

IFCT-1603 [63]

II R 2: 1

N = 64

1. Atezo

2. Etop+Carbo/Topotecan

6-week ORR, 2.3%, 10%

Median PFS, 1.4 m, 4.3 m

Median OS, 11.4 m, 9.4 m

G3-4

4.2%

~ 35%

OAK [64]

III R 1: 1

N = 850

1. Atezo

2. Docetaxel

ORR, 14%, 13%

Median PFS, 2.8 m, 4.0 m

Median OS, 13.8 m, 9.6 m

G3-4

15%

43%

PACIFIC [65]

III R 2: 1

N = 709

1. CRT+Durva

2. CRT+Placebo

Median PFS, 17.2 m, 5.6 m

Median OS, NR, 28.7 m

1-year OS, 66.3%, 55.6%

G3-4

30.5% 26.1%

CheckMate 451

III R 1: 1: 1

N = 810

1. Nivo

2. Nivo+Ipi

3. Placebo

Maintenance nivo/nivo+ipi did not improve OS

NA

NCT02359019 [66]

II N = 45

Pembro

Median PFS, 1.4 m

Median OS, 9.6 m

~ 15%